Prospective study evaluating IncobotulinumtoxinA for cervical dystonia or blepharospasm: Interim results from the first 145 subjects with cervical dystonia

Tremor and Other Hyperkinetic Movements

Volumn 1, Issue 1, 2013, Pages

  Fernandez, Hubert H ^a   Pagan, Fernando ^b   Danisi, Fabio ^c   Greeley, David ^d   Jankovic, Joseph ^e   Verma, Amit ^f   Sethi, Kapil ^f,g   Pappert, Eric J ^f  

^a LERNER RESEARCH INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^c Kingston Neurological Associates   (United States)

^d PLLC   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f Merz Pharmaceuticals LLC   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Botulinum toxin type A; CDIP 58; Cervical dystonia; IncobotulinumtoxinA; NT 201

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; BLEPHAROSPASM; CERVICAL DYSTONIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; ECHOGRAPHY; ELECTROMYOGRAPHY; ELECTROSTIMULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NECK PAIN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANGE OF MOTION; SCORING SYSTEM; SIDE EFFECT; SWELLING;

EID: 85202563348     PISSN: None     EISSN: 21608288     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Tarsy D, Simon DK. Dystonia. N Engl J Med 2006;355:818-829, http://dx.doi.org/10.1056/NEJMra055549.
2. Brashear A. Botulinum toxin type A in the treatment of patients with cervical dystonia. Biologics2009;3:1-7.
3. Brefel-Courbon C, Simonetta-Moreau M, More C, et al. A pharmacoeconomic evaluation of botulinum toxin in the treatment of spasmodic torticollis. Clin Neuropharmacol 2000;23:203-207, http://dx.doi.org/10.1097/ 00002826-200007000-00006.
4. Molho ES, Agarwal N, Regan K, et al. Effect of cervical dystonia on employment: a retrospective analysis of the ability of treatment to restore premorbid employment status. Mov Disord2009;24:1384-1387, http://dx.doi.org/10.1002/mds.22622.
5. Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1699-1706, http://dx.doi.org/10.1212&# x002F;01.wnl.0000311389.26145.95.
6. Merz Pharmaceuticals, LLC. FDA Approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical Dystonia and blepharospasm [press release August 2nd, 2010]. 2010;http://www.merzusa. com/pdf/FDA_Approval_of_Xeomin.pdf. Accessed August 3, 2010.
7. Merz Aesthetics, Inc. Merz Aesthetics announces FDA approval of Xeomin®(incobotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients [press release July 21st, 2011] 2011; http://www. merzaesthetics.com/en-US/news/announcing-xeomin.cfm. Accessed 11/17/2011.
8. Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005;64:1949-1951, http://dx.doi.org/10.1212&# x002F;01.WNL.0000163767.99354.C3.
9. Comella C, Jankovic J, Truong D, et al. Efficacy and safety of NT 201 (neurotoxin free from complexing proteins) in cervical dystonia (Abstract P07.088). Neurology 2009;72:A345.
10. Comella CL, Jankovic J, Truong DD, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 2011;308:103-109, http://dx.doi.org/10.1016/j.jns.2011. 05.041.
11. Grafe S, Hanschmann A. Safety and efficacy of repeated NT 201 (botulinum neurotoxin type A free from complexing proteins) injections of patients with cervical dystonia: a first long-term safety analysis (Abstract P01.270). Neurology 2010;74:A88, http://dx.doi.org/10.1212/ WNL.0b013e3181e04376.
12. Merz Pharmaceuticals, GmbH. Data on File. Frankfurt, Germany. 2011.
13. Cano SJ, Hobart JC, Edwards M, et al. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology 2006;67:2230-2232, http://dx.doi.org/10.1212&# x002F;01.wnl.0000249310.25427.f2.
14. Cano SJ, Hobart JC, Fitzpatrick R, et al. Patient-based outcomes of cervical dystonia: a review of rating scales. Mov Disord 2004;19:1054-1059, http://dx.doi.org/10.1002/mds.20055.
15. Cano SJ, Warner TT, Linacre JM, et al. Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58). Neurology 2004;63:1629-1633, http://dx.doi.org/10.1212&# x002F;01.WNL.0000142962.11881.26.
16. Cano SJ, Warner TT, Thompson AJ, et al. The cervical dystonia impact profile (CDIP-58): can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?Health Qual Life Outcomes 2008;6:58, http://dx.doi.org/10.1186/1477-7525-6-58.
17. Quality Metric. SF-12v2 Health Surveys. http://www.qualitymetric.com/ WhatWeDo/GenericHealthSurveys/SF12v2HealthSurvey/ tabid/186/Default.aspx. Accessed March 17, 2010.
18. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics Nov 1993;4:353-365, http://dx.doi.org/10.2165/ 00019053-199304050-00006.
19. Merz Pharmaceuticals, LLC. XEOMIN-(incobotulinumtoxinA) for injection US Prescribing Information. 2011:Version 07/2011.
20. Evidente VG, Fernandez HH, LeDoux MS, et al. Efficacy and safety of repeated incobotulinumtoxinA (Xeomin) injections in subjects with cervical dystonia: a randomized, double-blind extension study. The Journal of Neural Transmission 2013; Under Review.
21. Consky E, Basinski A, Belle L, et al. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability (Abstract 1199P). Neurology 1990; 40.
22. Consky E, Basinski A, Belle-Scantlebury L, et al. Comparison of botulinum toxin treatment variables for spasmodic torticollis (Abstract 562S). Neurology 1991;41:273.
23. Charles D, Brashear A, Hauser RA, et al. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol 2012;35(5):208-214, http://dx.doi.org/10.1097/ WNF.0b013e31826538c7.
24. Sethi KD, Rodriguez R, Olayinka B. Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 2012;15:419-423, http://dx.doi.org/10.3111/ 13696998.2011.653726.
25. Jankovic J, Adler CH, Charles PD, et al. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol 2011;11:140, http://dx.doi.org/10.1186/1471-2377-11-140.